FDA releases PDUFA VI program report on combination products

A new independent report on the FDA’s review practices for combination products under the Prescription Drug User Fee Act (PDUFA VI) gives the agency generally positive marks but finds room for refinements in communication and technology to improve the pre-submission and review process.